Efficacy of probiotic supplements on Parkinson's disease: A systematic review and meta-analysis

Complementary Therapies in Medicine, Journal Year: 2024, Volume and Issue: 82, P. 103045 - 103045

Published: May 4, 2024

This study aimed to evaluate the clinical efficacy and safety of probiotics supplementation in treatment Parkinson's disease (PD). We searched China National Knowledge Infrastructure (CNKI), Weipu (VIP) database, Wanfang Database, Sinomed (CBM), PubMed, Embase, Cochrane library Web Science databases for eligible studies from inception January 4th, 2024. Randomized controlled trials (RCTS) comparing effects probiotic supplements placebo patients with PD. Meta-analysis was conducted software Review Manager 5.4. The quality assessment performed according risk bias tool. A total 11 RCTs 756 PD were included this study. found that could increase number complete bowel movements (CBMs) per week improved scores Patient Assessment Constipation Quality Life Questionnaire (PAC-QOL) (SMD = 0.73, 95% CI: 0.54 - 0.92, P < 0.00001, I2 45%; SMD -0.79, -1.19 -0.39, 0.001, 55%, respectively) compared group. However, there no significant difference between two groups improving fecal traits defecation efforts 0.87, 0.01 1.74, 0.05, 94%; 1.24, -1.58 4.06, > 98%, respectively). In terms composite scale scores: after treatment, Movement Disorder Society-Unified-Parkinson Disease Rating Scale Ⅲ score (MDS-UPDRSⅢ) group -0.09, -0.35 0.16, 0%). conclusion, based on overall results available studies, our suggested potential value constipation symptoms patients. Therefore, may be one adjuvant therapy PD-related findings provide more proof supporting effectiveness probiotics, encouraging utilized alone or combination other therapies practice well-designed large sample sizes are required.

Language: Английский

---

The role of HLA-DR on plasmacytoid dendritic cells in mediating the effects of Butyrivibrio gut microbiota on Parkinson’s disease

Neurological Sciences, Journal Year: 2024, Volume and Issue: 45(8), P. 3809 - 3815

Published: March 19, 2024

Language: Английский

---

Gut microbiota’s role in glioblastoma risk, with a focus on the mediating role of metabolites

Frontiers in Neurology, Journal Year: 2024, Volume and Issue: 15

Published: July 3, 2024

This study employed Mendelian randomization (MR) analysis to systematically investigate the potential connections between gut microbiota and risk of glioblastoma (GBM). We identified 12 microbial groups closely associated with incidence GBM. Subsequently, MR was conducted on 1,091 blood metabolites 309 metabolite ratios, revealing 19 that exert an impact occurrence Hypothesizing may influence multiforme by modulating these metabolites, we performed analyses, considering each group as exposure outcome. Through constructed a regulatory network encompassing microbiota, GBM, providing novel perspective for deeper understanding role gut-brain axis in pathogenesis research offers crucial insights into how affect GBM regulating specific metabolites. The play significant formation development valuable information future therapeutic interventions.

Language: Английский

---

Rhapontin activates nuclear factor erythroid 2-related factor 2 to ameliorate 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced gastrointestinal dysfunction in Parkinson's disease mice

World Journal of Gastroenterology, Journal Year: 2025, Volume and Issue: 31(15)

Published: April 17, 2025

Parkinson's disease (PD)-a progressive neurodegenerative disorder-is characterized by motor and gastrointestinal dysfunction. The exploration of novel therapeutic strategies for PD is vital. To investigate the potential mechanism action rhapontin-a natural compound with known antioxidant anti-inflammatory properties-in context PD. Network pharmacology was used to predict targets mechanisms rhapontin in Behavioral tests tyrosine hydroxylase immunofluorescence analysis were assess effect on symptoms pathology MPTP-induced mice. Interleukin (IL)-6, IL-1β, tumor necrosis factor (TNF)-α, IL-10 levels tissues measured using an enzyme-linked immunosorbent assay (ELISA). Additionally, nuclear erythroid 2-related 2 (NRF2) activation confirmed western blotting. NRF2 predicted be key transcription underlying effects PD, its anti-PD may associated properties. Rhapontin ameliorated loss dopaminergic neurons dysfunction 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mice activating NRF2. treatment significantly decreased pro-inflammatory cytokines (IL-6, TNF-α, IL-1β) substantia nigra, striatum, colon, whereas it increased cytokine (IL-10) only indicating involvement gut-brain axis neuroprotective potential. Finally, identified as a activated rhapontin, particularly colon. We elucidated mouse models combination network analysis, behavioral assessments, immunofluorescence, ELISA, Western Our findings revealed multifaceted role ameliorating through properties, NRF2, paving way future research into targeted therapies

Language: Английский

---

Parkinson's disease and gut microbiota metabolites: The dual impact of vitamins and functional amyloids

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, Journal Year: 2025, Volume and Issue: 1871(6), P. 167862 - 167862

Published: April 18, 2025

Language: Английский

---

The microbiome’s influence on obesity: mechanisms and therapeutic potential

Science China Life Sciences, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 28, 2024

Language: Английский

---

Deciphering the Microbial Map and its implications in the therapeutics of Neurodegenerative Disorder

Ageing Research Reviews, Journal Year: 2024, Volume and Issue: 100, P. 102466 - 102466

Published: Aug. 27, 2024

Language: Английский

---